Welcome to Action Kidney Cancer

The United Kingdom’s only patient-led kidney cancer charity

Help & support

Community Forum

Stronger together

Join now

In our own words

During this series of videos, kidney cancer patients and carers talk frankly about their experiences, emotions and how to live well with a diagnosis of kidney cancer
Coping with a diagnosis of kidney cancer
Talking about kidney cancer
A carer’s perspective
Watch all

Real stories

The lives of all these people have been affected by kidney cancer
Some are patients, some are carers, all are stories by real people sharing their experiences of living with kidney cancer
Read real stories

Latest kidney cancer news

17 May 2022

Neoadjuvant axitinib may enable partial nephrectomy of complex kidney tumours

17 May 2022

Quality of life on lenvatinib plus pembrolizumab combination

16 May 2022

Transforming lives, raising productivity

13 May 2022

Tougher cancer diagnostic target as part of government's 'war on cancer'

12 May 2022

Breakthrough COVID-19 infections in vaccinated cancer patients

11 May 2022

MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer

11 May 2022

Treatment of local recurrence of kidney cancer after nephrectomy

3 May 2022

Treatment of people who relapse on adjuvant pembrolizumab

3 May 2022

Moderna’s COVID-19 vaccine may be more effective for cancer patients

3 May 2022

Kidney cancer patient summit on immunotherapy/TKI combinations

27 Apr 2022

Metastasectomy and survival in kidney cancer patients

26 Apr 2022

Cabozantinib for collecting duct carcinoma

Check all news
A recent study, the health-related quality of life (HRQoL) of patients in the phase 3 CLEAR study are discussed. All 1069 patients in the study were followed up for just over a year for quality of life assessments.
Read more on our website: https://t.co/JXoisK7EAk
#kidneycancer https://t.co/NoRUmJ9phy
ACTION4KC photo
The Association of the British Pharmaceutical Industry (ABPI) has commissioned a report about access to medicines in the UK. The NHS has made progress. However, access to medicines in the UK remains poor, especially compared to other developed countries. https://t.co/uWZz5ZL7zn https://t.co/zWIlei5wLR ACTION4KC photo
O is for Our real stories
We are looking for people to share their experience of living with kidney cancer, or if you have been on a clinical trial, or you have a loved one living with a #kidneycancer diagnosis with us, for our real stories page.
https://t.co/Y2sUh84XXc https://t.co/gXAfsYixjq
ACTION4KC photo
Save the date 16 June 2022 to take part in World Kidney Cancer Day and raise awareness of clinical trials and access to treatments for #kidneycancer patients.
To improve the lives of patients worldwide ‘We need to talk’.
For more info:
https://t.co/wPwUYXhRFR https://t.co/LLSlAXcEtF
ACTION4KC photo
N is for newsletter
Our newsletter is easy to read, friendly, and provides information about #kidneycancer.
If you would like to receive a copy via email, please subscribe by completing the form at the bottom of the web page below #bypatientsforpatients
https://t.co/qbOpq9qguP https://t.co/kFehdRCDC6
ACTION4KC photo
The aim of a phase 2 study was to compare MEDI0680 plus durvalumab with nivolumab in #kidneycancer patients who had not been treated with immunotherapy before, but who had been treated with a targeted therapy.
To find out more about the study: https://t.co/eB1EOd694l https://t.co/HiGploabQ6
ACTION4KC photo
Follow on Twitter
Action Kidney Cancer
Action Kidney Cancer
A new study called CAPER has started recruiting patients in the UK. This study is looking at a new combination of two medicines called cyclophosphamide and pembrolizumab for the treatment of people with kidney cancer (renal cell carcinoma, RCC) that is not possible to remove with an operation or has spread to other parts of the body.

It is for people who have already had a first-line treatment with a type of medicine called an immunotherapy (nivolumab, ipilimumab, pembolizumab).

The sites are at the Royal Marsden in London, the Christie in Manchester, the Western General in Edinburgh, and Addenbrookes in Cambridge. For more information, please visit our clinical trials database: https://clinmapstaging.wpengine.com/?job_listing=caper-a-study-of-cyclophosphamide-and-pembrolizumab-for-kidney-cancer-3
Action Kidney Cancer
Action Kidney Cancer
Just over half of the patients from a phase 2 clinical trial looking at giving axitinib to shrink the kidney cancer tumour before surgery (neoadjuvant axitinib) have been looked at. In these 26 patients, kidney tumour size and complexity were significantly reduced. This enabled the patients to have partial nephrectomy, despite the tumours being complicated.

Read more on our website here: https://actionkidneycancer.org/neoadjuvant-axitinib-may-enable-partial-nephrectomy-in-complex-renal-tumors/
Action Kidney Cancer
Action Kidney Cancer
In a recent study, the health-related quality of life (HRQoL) of patients in the phase 3 CLEAR study are discussed. There were 1069 patients in the study and all were followed up for just over a year for quality of life assessments.

Read more on our website here: https://actionkidneycancer.org/quality-of-life-on-lenvatinib-plus-pembrolizumab-combination/
Action Kidney Cancer
Action Kidney Cancer
The Association of the British Pharmaceutical Industry (ABPI) has commissioned a report about access to medicines in the UK. The NHS has made progress towards making some of the most exciting new medicines and vaccines available to patients. However, the report shows that access to medicines in the UK remains poor, especially compared to other developed countries. Three areas need improvement.

Read more on our website: https://actionkidneycancer.org/transforming-lives-raising-productivity/
Action Kidney Cancer
Action Kidney Cancer
Government is considering setting a tougher cancer diagnostic target as part of its declared ‘war on cancer’, the Health Service Journal (HSJ) has been told.

Read the full HSJ article on our website here: https://actionkidneycancer.org/tougher-cancer-diagnostic-target-as-part-of-governments-war-on-cancer/
Action Kidney Cancer
Action Kidney Cancer
O is for Our real stories

We know that the Real stories page is one of the most visited on our website and many of our community find great hope and inspiration from sharing and reading each others experiences.

We are looking for people to share their experience of living with kidney cancer, or if you have been on a clinical trial. Finally any loved ones who wish to share their experience of living with a family member or friend with a kidney cancer diagnosis.

If you would like to help us in this way we can provide any help you may require.
Please email karen@actionkidneycancer.org if this is something that you would like to be involved with.

To visit our real stories page on the website please follow the link below:
https://actionkidneycancer.org/help-support/real-stories/

#kidneycancer #bypatientsforpatients #StrongerTogether
Follow on Facebook